Fintel reports that on August 15, 2023, Goldman Sachs maintained coverage of 2seventy bio (NASDAQ:TSVT) with a Buy recommendation. As of August 2, 2023, the average one-year price target for 2seventy ...

Boundless Bio, a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) to develop therapies for oncogene amplified cancers, announced that its CEO Zachary Hornby will participate in ...

In a report released yesterday, Chris Shibutani from Goldman Sachs maintained a Buy rating on Gossamer Bio (GOSS – Research Report). The company’s shares closed yesterday at $1.25. Shibutani covers ...

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with ...

The Goldman Sachs Group, Inc. is an American multinational investment bank and financial services company. Founded in 1869, Goldman Sachs is headquartered in Lower Manhattan in New York City, with ...

As of August 2, 2023, the average one-year price target for 2seventy bio is 25.50. The forecasts range from a low of 13.13 to a high of $34.65. The average price target represents an increase of ...

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (BOLD) (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative ...